Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

By A. Roth, S. Tejpar, Mauro Delorenzi, P. Yan, R. Fiocca, D. Klingbiel, D. Dietrich, B. Biesmans, G. Bodoky, C. Barone and 7 more. Journal of Clinical Oncology, 2010

1,156 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/a9a81ce530127069b5c1223dc6c3a349f771897a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Quirke
2. I. Nagtegaal
3. S. Venderbosch
4. T. Maughan
5. Christopher G. Smith
6. J. Cheadle
7. A. D. de Haan
8. G. Meijer

Citations in the corpus

• Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies (2014, background): “(14) BRAFMT has a negative prognostic impact, although this may be restricted to patients with proficient MMR (pMMR) tumors.(15, 16) Data on the role of BRAF in relation to MMR status in mCRC are scarce and are derived from small subsets of selected patients.”